GB0428263D0 - Compounds - Google Patents

Compounds

Info

Publication number
GB0428263D0
GB0428263D0 GB0428263A GB0428263A GB0428263D0 GB 0428263 D0 GB0428263 D0 GB 0428263D0 GB 0428263 A GB0428263 A GB 0428263A GB 0428263 A GB0428263 A GB 0428263A GB 0428263 D0 GB0428263 D0 GB 0428263D0
Authority
GB
United Kingdom
Prior art keywords
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB0428263A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to GB0428263A priority Critical patent/GB0428263D0/en
Publication of GB0428263D0 publication Critical patent/GB0428263D0/en
Priority to EP05817767A priority patent/EP1833795B1/en
Priority to CA002592442A priority patent/CA2592442A1/en
Priority to CNA2005800486057A priority patent/CN101128430A/en
Priority to JP2007547393A priority patent/JP2008525363A/en
Priority to MX2007007830A priority patent/MX2007007830A/en
Priority to EP09150218A priority patent/EP2053042A1/en
Priority to KR1020077014271A priority patent/KR20070091301A/en
Priority to DE602005013116T priority patent/DE602005013116D1/en
Priority to ARP050105412A priority patent/AR052429A1/en
Priority to US11/722,402 priority patent/US20100137378A1/en
Priority to AT05817767T priority patent/ATE424386T1/en
Priority to AU2005318372A priority patent/AU2005318372A1/en
Priority to ES05817767T priority patent/ES2321535T3/en
Priority to EA200701324A priority patent/EA200701324A1/en
Priority to TW094145424A priority patent/TW200640865A/en
Priority to AP2007004017A priority patent/AP2007004017A0/en
Priority to BRPI0519398-2A priority patent/BRPI0519398A2/en
Priority to UY29298A priority patent/UY29298A1/en
Priority to PCT/EP2005/014061 priority patent/WO2006066968A1/en
Priority to EA200801909A priority patent/EA200801909A1/en
Priority to PE2006000025A priority patent/PE20060838A1/en
Priority to PE2008001431A priority patent/PE20081440A1/en
Priority to MA29966A priority patent/MA29082B1/en
Priority to IL183781A priority patent/IL183781A0/en
Priority to US11/766,418 priority patent/US7759369B2/en
Priority to NO20073332A priority patent/NO20073332L/en
Ceased legal-status Critical Current

Links

GB0428263A 2004-12-23 2004-12-23 Compounds Ceased GB0428263D0 (en)

Priority Applications (27)

Application Number Priority Date Filing Date Title
GB0428263A GB0428263D0 (en) 2004-12-23 2004-12-23 Compounds
EA200801909A EA200801909A1 (en) 2004-12-23 2005-12-21 PYRIDINE COMPOUNDS FOR THE TREATMENT OF DISEASES MEDIATED BY PROSTAGLANDINE
AU2005318372A AU2005318372A1 (en) 2004-12-23 2005-12-21 Pyridine compounds for the treatment of prostaglandin mediated diseases
EA200701324A EA200701324A1 (en) 2004-12-23 2005-12-21 PYRIDINE COMPOUNDS FOR THE TREATMENT OF DISEASES MEDIATED BY PROSTAGLANDINE
CNA2005800486057A CN101128430A (en) 2004-12-23 2005-12-21 Pyridine compounds for the treatment of prostaglandin mediated diseases
JP2007547393A JP2008525363A (en) 2004-12-23 2005-12-21 Pyridine compounds for the treatment of prostaglandin-mediated diseases
MX2007007830A MX2007007830A (en) 2004-12-23 2005-12-21 Pyridine compounds for the treatment of prostaglandin mediated diseases.
EP09150218A EP2053042A1 (en) 2004-12-23 2005-12-21 Pyridine compounds for the treatment of prostaglandin mediated diseases
KR1020077014271A KR20070091301A (en) 2004-12-23 2005-12-21 Pyridine compounds for the treatment of prostaglandin mediated diseases
DE602005013116T DE602005013116D1 (en) 2004-12-23 2005-12-21 PYRIDINE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN-MEDIATED DISEASES
ARP050105412A AR052429A1 (en) 2004-12-23 2005-12-21 ARILPIRIDINE COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT AND PROCEDURE TO PREPARE IT
US11/722,402 US20100137378A1 (en) 2004-12-23 2005-12-21 Pyridine Compounds For The Treatment Of Prostaglandin Mediated Diseases
AT05817767T ATE424386T1 (en) 2004-12-23 2005-12-21 PYRIDINE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN-MEDIATED DISEASES
EP05817767A EP1833795B1 (en) 2004-12-23 2005-12-21 Pyridine compounds for the treatment of prostaglandin mediated diseases
ES05817767T ES2321535T3 (en) 2004-12-23 2005-12-21 PIRIDINE COMPOUNDS FOR THE TREATMENT OF DISEASES MEDIATED BY PROSTAGLANDINAS.
CA002592442A CA2592442A1 (en) 2004-12-23 2005-12-21 Pyridine compounds for the treatment of prostaglandin mediated diseases
TW094145424A TW200640865A (en) 2004-12-23 2005-12-21 Compounds
AP2007004017A AP2007004017A0 (en) 2004-12-23 2005-12-21 Pyridine compounds for the treatment of prostaglandin mediated diseases
BRPI0519398-2A BRPI0519398A2 (en) 2004-12-23 2005-12-21 Pyridine Compounds for the Treatment of Prostaglandin-Mediated Diseases
UY29298A UY29298A1 (en) 2004-12-23 2005-12-21 COMPOUNDS
PCT/EP2005/014061 WO2006066968A1 (en) 2004-12-23 2005-12-21 Pyridine compounds for the treatment of prostaglandin mediated diseases
PE2006000025A PE20060838A1 (en) 2004-12-23 2006-01-03 6- [(5 - CHLORINE - 2 - {[(4-CHLORO-2-FLUOROPHENYL) METHYL] OXY} PHENYL) METHYL] -2-PYRIDINECARBOXYL ACID, SALTS OF IT, AS WELL AS COMPOSITIONS THAT INCLUDE IT
PE2008001431A PE20081440A1 (en) 2004-12-23 2006-01-30 PYRIDINE DERIVATIVES AS ANTAGONISTS OF EP1 PROSTAGLANDIN RECEPTORS
MA29966A MA29082B1 (en) 2004-12-23 2007-06-06 PYRIDINE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN-MEDIATED DISEASES
IL183781A IL183781A0 (en) 2004-12-23 2007-06-07 Pyridine compounds for the treatment of prostaglandin mediated diseases
US11/766,418 US7759369B2 (en) 2004-12-23 2007-06-21 Pyridine compounds for the treatment of prostaglandin mediated diseases
NO20073332A NO20073332L (en) 2004-12-23 2007-06-28 Pyridine compounds for the treatment of prostaglandin-mediated diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0428263A GB0428263D0 (en) 2004-12-23 2004-12-23 Compounds

Publications (1)

Publication Number Publication Date
GB0428263D0 true GB0428263D0 (en) 2005-01-26

Family

ID=34113190

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0428263A Ceased GB0428263D0 (en) 2004-12-23 2004-12-23 Compounds

Country Status (3)

Country Link
CN (1) CN101128430A (en)
AP (1) AP2007004017A0 (en)
GB (1) GB0428263D0 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201107309A (en) * 2009-07-27 2011-03-01 Kissei Pharmaceutical Indole derivatives, or the pharmaceutically acceptable salts
EP2570125A1 (en) * 2011-09-16 2013-03-20 Almirall, S.A. Ep1 receptor ligands

Also Published As

Publication number Publication date
CN101128430A (en) 2008-02-20
AP2007004017A0 (en) 2007-06-30

Similar Documents

Publication Publication Date Title
GB0405933D0 (en) Compounds
EP1737831A4 (en) Neurologically-active compounds
GB0405937D0 (en) Compounds
EP1755617A4 (en) Perfluorocarbon-soluble compounds
GB0405193D0 (en) Compounds
GB0405272D0 (en) Compounds
GB0405267D0 (en) Compounds
GB0405101D0 (en) Compounds
GB0408772D0 (en) Compounds
GB0401269D0 (en) Compounds
GB0405280D0 (en) Compounds
GB0428263D0 (en) Compounds
GB0403593D0 (en) Compounds
GB0405893D0 (en) Compounds
GB0406916D0 (en) Compounds
GB0403595D0 (en) Compounds
GB0404083D0 (en) Compounds
GB0405230D0 (en) Compounds
GB0405099D0 (en) Compounds
GB0404215D0 (en) Compounds
GB0405194D0 (en) Compounds
GB0400716D0 (en) Compounds
GB0404104D0 (en) Compounds
GB0404084D0 (en) Compounds
GB0403998D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)